Company Encyclopedia
View More
name
BHC
600721.SH
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. It also offers comprehensive contract research organization (CRO) solutions, including one-stop, full-process services for drug R&D, such as Phase I to IV clinical trials, bioequivalence and pharmacokinetics testing, medical science services, R&D project consulting, data management and statistical services, and third-party testing, which covers biological sample analysis, packaging material compatibility, and base toxic impurity analysis. The company was formerly known as Xinjiang Baihuacun Co., Ltd. and changed its name to Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd in July 2021.
3.095 T
600721.SHMarket value -Rank by Market Cap -/-

Financial Score

29/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking148/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.55%C
    • Profit Margin12.75%B
    • Gross Margin61.53%A
  • Growth ScoreC
    • Revenue YoY-0.12%D
    • Net Profit YoY161.00%A
    • Total Assets YoY-0.59%D
    • Net Assets YoY7.27%B
  • Cash ScoreC
    • Cash Flow Margin784.32%B
    • OCF YoY-0.12%D
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreB
    • Gearing Ratio29.16%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BHC: The net profit for the third quarter was 7.1908 million yuan, a year-on-year increase of 456.45%

    BHC announced that its revenue for the third quarter was 96.5195 million yuan, a year-on-year increase of 2.32%; net profit was 7.1908 million yuan, a year-on-year increase of 456.45%. Revenue for the first three quarters was 299 million yuan, a year-on-year increase of 2.74%; net profit was 32.6742 million yuan, a year-on-year increase of 36.41%

    Zhitong·
    SH
    600721
    0.00%
    Zhitong·
    SH
    600721
    0.00%

    The concept of innovative drugs rebounds, BHC and HWHG hit the limit up

    The innovative drug concept rebounded. As of the time of publication, BHC and HWHG hit the daily limit, while Boteng Co., Ltd., Rejing Biotech, and Heng Rui Medicine saw significant gains

    Zhitong·
    SH
    600721
    0.00%
    SH
    600079
    -3.08%
    Zhitong·
    SH
    600721
    0.00%
    SH
    600079
    -3.08%

    BHC released its performance for the first half of the year, with a net profit attributable to the parent company of 25.4834 million yuan, a year-on-year increase of 12.45%

    BHC released its semi-annual report for 2025, reporting operating revenue of 202 million yuan, a year-on-year increase of 2.95%; net profit attributable to the parent company of 25.4834 million yuan, a year-on-year increase of 12.45%; net profit excluding non-recurring gains and losses of 24.0587 million yuan, a year-on-year increase of 13.82%; basic earnings per share of 0.0663 yuan

    Zhitong·
    SH
    600721
    0.00%
    Zhitong·
    SH
    600721
    0.00%

    The concept of weight loss drugs continues to strengthen, BHC hits the daily limit

    The concept of weight loss drugs continues to strengthen, BHC hits the limit up, and Hanyu Pharmaceutical, Jinkai Biotechnology, Shengnuo Biotech, Keyuan Pharmaceutical, ST Nuotai, Lepu Medical, and others follow suit

    Zhitong·
    SH
    600721
    0.00%
    Zhitong·
    SH
    600721
    0.00%

    BHC: Director Sun Jianbin resigns for personal reasons

    BHC announced that Mr. Sun Jianbin, a director of the company, has applied to resign from his positions as a director, a member of the board's audit committee, and a member of the board's compensation and assessment committee for personal reasons. Mr. Sun Jianbin's resignation will take effect from the date the resignation report is delivered to the company. According to relevant regulations, Mr. Sun Jianbin's resignation will not affect the normal operation of the board and the company's business. The company will complete the election of a new director as soon as possible

    Zhitong·
    SH
    600721
    0.00%
    Zhitong·
    SH
    600721
    0.00%
    © 2025 Longbridge｜Disclaimer